Kinarus Therapeutics Holding AG announced the signing of a strategic convertible loan agreement for a CHF 1.5 million on May 10, 2023. The transaction will include participation from new investor, ChaoDian (Hangzhou) Investment Management Co., Ltd. Under the terms of the loan agreement, the subordinated loan have a fixed term of three years without any interest. During the term of the agreement, the outstanding loan amount can be converted at any time into shares with a nominal value of CHF 0.01 at a fixed conversion price of CHF 0.01 per share.